France-based Biomunex Pharmaceuticals has signed a licensing agreement with France-based Sanofi.

It was reported yesterday that the contract has been signed for the development of bi-specific and multi-specific antibody therapeutics. Under the contract, Sanofi will use Biomunex's BiXAb platform to generate and improve bi-specific and multi-specific antibodies. Sanofi will take responsibility for the research, development, manufacturing and global commercialisation activities of new antibody therapeutics. Under the terms of the deal, Biomunex will secure an initial upfront payment and further clinical, regulatory and commercial milestone payments.

Biomunex plug-and-play BiXAb is a universal modular bi-specific and multi-specific format, enabling the platform to format from any pair of monospecific monoclonal antibodies as building blocks in a timely and cost-effective manner. The company is using the platform to develop immune-oncology drug candidates with high anti-tumour activity.